Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
Front Pharmacol ; 10: 1051, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31619997

RESUMO

Adenosine can be released from the heart and may stimulate four different cardiac adenosine receptors. A receptor subtype that couples to the generation of cyclic adenosine monophosphate (cAMP) is the A2A-adenosine receptor (A2A-AR). To better understand its role in cardiac function, we studied mechanical and electrophysiological effects in transgenic mice that overexpress the human A2A-AR in cardiomyocytes (A2A-TG). We used isolated preparations from the left atrium, the right atrium, isolated perfused hearts with surface electrocardiogram (ECG) recording, and surface body ECG recordings of living mice. The hypothesized arrhythmogenic effects of transgenicity per se and A2A-AR stimulation were studied. We noted an increase in the incidence of supraventricular and ventricular arrhythmias under these conditions in A2A-TG. Moreover, we noted that the A2A-AR agonist CGS 21680 exerted positive inotropic effect in isolated human electrically driven (1 Hz) right atrial trabeculae carneae. We conclude that A2A-ARs are functional not only in A2A-TG but also in isolated human atrial preparations. A2A-ARs in A2A-TG per se and their stimulation can lead to cardiac arrhythmias not only in isolated cardiac preparations from A2A-TG but also in living A2A-TG.

2.
Front Pharmacol ; 9: 13, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29403384

RESUMO

Background: Adenosine can be produced in the heart and acts on cardiac adenosine receptors. One of these receptors is the A2A-adenosine receptor (A2A-AR). Methods and Results: To better understand its role in cardiac function, we generated and characterized mice (A2A-TG) which overexpress the human A2A-AR in cardiomyocytes. In isolated atrial preparations from A2A-TG but not from WT, CGS 21680, an A2A-AR agonist, exerted positive inotropic and chronotropic effects. In ventricular preparations from A2A-TG but not WT, CGS 21680 increased the cAMP content and the phosphorylation state of phospholamban and of the inhibitory subunit of troponin in A2A-TG but not WT. Protein expression of phospholamban, SERCA, triadin, and junctin was unchanged in A2A-TG compared to WT. Protein expression of the α-subunit of the stimulatory G-protein was lower in A2A-TG than in WT but expression of the α-subunit of the inhibitory G-protein was higher in A2A-TG than in WT. While basal hemodynamic parameters like left intraventricular pressure and echocardiographic parameters like the systolic diameter of the interventricular septum were higher in A2A-TG than in WT, after ß-adrenergic stimulation these differences disappeared. Interestingly, A2A-TG hearts sustained global ischemia better than WT. Conclusion: We have successfully generated transgenic mice with cardiospecific overexpression of a functional A2A-AR. This receptor is able to increase cardiac function per se and after receptor stimulation. It is speculated that this receptor may be useful to sustain contractility in failing human hearts and upon ischemia and reperfusion.

3.
Platelets ; 23(2): 150-6, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-21806498

RESUMO

All deleterious changes in platelet morphology, structure and function that occur in platelet concentrates (PC) during storage are titled as the 'platelet storage lesion'. No single in vitro test currently available is sufficient in assessing these changes of platelet quality. The release of soluble CD40 Ligand (sCD40L), the formation of thromboxane (TXB2) and the thrombopoietin (TPO) clearance reflect different aspects of platelet metabolism and activitiy, and were used to examine platelet quality in apheresis platelet products. At days 1, 3 and 5, in single-donor apheresis platelet products (n = 10) under routine storage conditions, sCD40L (measured by ELISA) and TXB2 (measured by RIA) were determined after platelet stimulation (recalcification and clot formation). TPO (measured by ELISA) was determined after an incubation time of 5 h at 37°C with platelet-rich plasma (adjusted initial TPO concentration of about 500 pg/mL). Results were related to a therapeutic unit (TU = 2 × 10(11) platelets). Immediately after platelet preparation, sCD40L release was 41 ± 7.6 ng/TU, TXB2 formation 1688 ± 374 ng/TU and TPO clearance 1.22 ± 0.32 ng/h/TU. At days 1, 3 and 5, sCD40L was reduced to 89 ± 7%, 71 ± 12% and 57 ± 9%, TXB2 release to 91 ± 6%, 74 ± 12% and 58 ± 9% and TPO clearance to 90 ± 15%, 84 ± 5% and 79 ± 10% of the respective control values. In conclusion, in single-donor apheresis PC, sCD40L release and TXB2 formation as well as TPO clearance by the platelets were dependent on storage duration and reduced to about 60% to 80% of the respective control values after a storage period for 5 days. These findings are in line with literature data, indicating that a loss of platelet functionality of about 30% will occur after 5 days of storage.


Assuntos
Ligante de CD40/sangue , Ativação Plaquetária/fisiologia , Plaquetoferese/métodos , Trombopoetina/sangue , Tromboxano B2/biossíntese , Adulto , Remoção de Componentes Sanguíneos , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Masculino , Contagem de Plaquetas , Testes de Função Plaquetária , Radioimunoensaio , Tromboxano B2/sangue
4.
Clin Hemorheol Microcirc ; 49(1-4): 399-406, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22214710

RESUMO

INTRODUCTION: The hormones erythropoietin (EPO) and thrombopoietin (TPO) are main regulators of erythro- and thrombopoiesis. Cell loss caused by operative procedures may alter serum levels of the hormones, resulting in well known phenomenons like reactice thrombocytosis. MATERIAL AND METHODS: Blood samples from 10 patients (mean age 63 ± 9 years) were obtained before and at day 1, 5 and 10 after coronary artery bypass grafting (CABG). EPO and TPO levels were determined by commercially available ELISA-Kits (R&D Systems, Germany). In addition, platelet count (PC) and hemoglobin concentration (Hb) were determined. RESULTS: Prior to CABG, EPO (13.2 ± 8.2 mU/mL), TPO (189 ± 52 pg/mL), Hb (8.8 ± 1.1 mmol/L) and PC (254 ± 121/nL) were within a normal range. At day 1 after surgery, Hb and PC were significantly decreased to 6.6 ± 0.9 mmol/L and 138 ± 70/nL. In contrast, EPO and TPO were significantly elevated to 32 ± 18 mU/mL and 336 ± 96 pg/mL, respectively, in spite of hemodilution. In particular, TPO elevation was followed by a significant increase in PC (342 ± 144/nL) at day 10 after surgery compared to preoperative values. CONCLUSIONS: Appropriate to the decrease in hemoglobin concentration and platelet count, clear alterations of serum erythropoietin and thrombopoietin levels could postoperatively be observed. EPO levels showed an inverse correlation to hemoglobin concentrations, whereas a disturbed thrombopoietin feedback mechanism resulted in the phenomenon of reactive thrombocytosis.


Assuntos
Ponte de Artéria Coronária , Eritropoetina/sangue , Trombopoetina/sangue , Idoso , Anemia/sangue , Anemia/complicações , Doença das Coronárias/sangue , Doença das Coronárias/complicações , Doença das Coronárias/cirurgia , Procedimentos Cirúrgicos Eletivos , Retroalimentação Fisiológica , Feminino , Hemoglobinas/análise , Humanos , Masculino , Pessoa de Meia-Idade , Contagem de Plaquetas , Período Pós-Operatório
5.
Thromb Haemost ; 100(3): 379-90, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18766252

RESUMO

Aspirin reduces major atherothrombotic events across a wide spectrum of patients with atherosclerotic disease. The occurrence of ischemic events despite of aspirin treatment is a failure of therapy, often denoted 'clinical aspirin resistance'. This is distinguished from laboratory assays showing an insufficient inhibition of platelet function, which indicate 'laboratory aspirin resistance'. Laboratory aspirin resistance has been reported in up to 60% of patients after stroke or peripheral arterial disease, up to 70% in stable coronary heart disease and even up to 80% in acute myocardial infarction. However, this data must be interpreted carefully because of small sample sizes and potential confounding factors such as compliance, co-morbidities and large differences between the laboratory methods used for detection. During the past years, evidence has accumulated that laboratory aspirin resistance is associated with an increased incidence of major atherothrombotic events, with an up to 13-fold increased risk of events in patients with cardiovascular disease. Thus, an individualized antiplatelet therapy will have to consider the possibility of aspirin resistance, and the identification of aspirin non-responders may improve antiplatelet therapy in future. Whether an increased dose of aspirin or another antiplatelet drug (e.g. clopidogrel) instead or in addition to aspirin should be given is unclear. Prospective trials are underway which address this issue. This review gives an overview on the various clinical studies that have investigated the prevalence and clinical importance of laboratory aspirin resistance. Moreover, therapeutic options, as well as future perspectives are discussed.


Assuntos
Aspirina/farmacologia , Resistência a Medicamentos , Aterosclerose/tratamento farmacológico , Ensaios Clínicos como Assunto , Clopidogrel , Doença das Coronárias/complicações , Doença das Coronárias/tratamento farmacológico , Humanos , Isquemia/tratamento farmacológico , Isquemia/prevenção & controle , Projetos de Pesquisa , Acidente Vascular Cerebral/complicações , Acidente Vascular Cerebral/tratamento farmacológico , Trombose/diagnóstico , Ticlopidina/análogos & derivados , Ticlopidina/farmacologia , Resultado do Tratamento
6.
Herz ; 33(4): 270-8, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18581076

RESUMO

Recent clinical studies have shown that the expected antiplatelet effect of aspirin is not always achieved. From the laboratory point of view, resistance to aspirin is the inability to achieve the expected inhibition of platelet cyclooxygenase-(COX-)1 with prevention of platelet thromboxane (TX) A2 formation. The failure to prevent atherothrombotic events (treatment failure) must be distinguished from aspirin resistance. Nevertheless, different definitions of aspirin resistance complicate the assessment of published data, a problem aggravated by discordant results of the available diagnostic laboratory techniques.The pharmacological mechanisms of aspirin resistance are not completely understood. Potential causes include pharmacokinetic and pharmacodynamic issues, such as reduced bioavailability, increased platelet turnover, interactions with nonsteroidal anti-inflammatory drugs, comorbidities (hypercholesterolemia or diabetes mellitus), alternative pathways of platelet activation, and genetic polymorphisms. Clinical trials demonstrated a negative impact of aspirin resistance on the clinical outcome: an about fourfold increased risk of major atherothrombotic events has been found in aspirin nonresponders suffering from vascular disease.An individualized antiplatelet therapy with aspirin will have to consider the possibility of aspirin resistance. Thus, standardized and inexpensive diagnostic assays are needed. The identification of aspirin-resistant patients is essential to individually tailor antiplatelet treatment. For example, increasing the dosage of aspirin or alternative antiplatelet drugs are potential therapeutic concepts, but these require careful future investigation.


Assuntos
Angioplastia Coronária com Balão/efeitos adversos , Aspirina/administração & dosagem , Prótese Vascular/efeitos adversos , Trombose Coronária/etiologia , Trombose Coronária/prevenção & controle , Resistência a Medicamentos , Stents/efeitos adversos , Relação Dose-Resposta a Droga , Esquema de Medicação , Humanos , Padrões de Prática Médica/tendências
7.
Eur J Cardiothorac Surg ; 34(1): 93-108, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18448350

RESUMO

The success of coronary artery bypass graft surgery (CABG) depends mainly on the patency of the graft vessels. Aortocoronary vein graft disease is comprised of three distinct but interrelated pathological processes: thrombosis, intimal hyperplasia and atherosclerosis. Early thrombosis is a major cause of vein graft attrition during the first month after CABG, while during the remainder of the first year, intimal hyperplasia forms a template for subsequent atherogenesis, which thereafter predominates. Platelets play a crucial role in the pathophysiology of graft thrombosis and aspirin is the primary antiplatelet drug that has been shown to improve vein graft patency within the first year after CABG. Nevertheless, a significant number of grafts still occlude in the early postoperative period despite 'appropriate' aspirin treatment. Moreover, laboratory investigations showed that the expected inhibition of platelet function is not always achieved. This has been called 'aspirin nonresponse' or 'aspirin resistance', although a uniform definition is lacking. The finding that a considerable number of patients show an impaired antiplatelet effect of aspirin after CABG brought new insight into the discussion concerning poor patency rates of bypass grafts: the early period after CABG shows a coincidence of an increased risk for bypass thrombosis (amongst others, due to platelet activation and endothelial cell disruption of the graft) and an increased prevalence of aspirin resistance. Hitherto, the underlying mechanisms of aspirin resistance are uncertain and largely hypothetical; amongst others, increased platelet turnover, enhanced platelet reactivity, systemic inflammation, and drug-drug interaction are discussed. Up to now available data concerning the clinical outcome of aspirin resistant CABG patients are limited, and there is evidence that platelets of patients with graft thrombosis are more likely to be resistant to aspirin compared with patients without thrombotic events. Many publications concerning aspirin resistance are available today, but reports addressing this topic in CABG patients are sparse. This review summarises recent insights into the antiplatelet treatment after CABG and describes the clinical benefit, but also the therapeutic failure of the well-established drug aspirin. Moreover, possible pharmacological approaches to improve antithrombotic therapy in aspirin nonresponders among CABG patients are discussed.


Assuntos
Aspirina/uso terapêutico , Ponte de Artéria Coronária , Fibrinolíticos/uso terapêutico , Aspirina/administração & dosagem , Esquema de Medicação , Resistência a Medicamentos , Fibrinolíticos/administração & dosagem , Oclusão de Enxerto Vascular/prevenção & controle , Humanos , Assistência Perioperatória/métodos , Inibidores da Agregação Plaquetária/administração & dosagem , Inibidores da Agregação Plaquetária/uso terapêutico
9.
Bioorg Med Chem Lett ; 18(2): 527-31, 2008 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-18068982

RESUMO

An unexpected ring contraction of benzazepinone based alpha(nu)beta(3) antagonists led to the design of quinolinone-type derivatives. Novel and efficient synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates were established. Nanomolar alpha(nu)beta(3) antagonists based on these new scaffolds were prepared. Moreover, benzoxazinones 15a and 15b exhibited high microsomal stability and good permeability.


Assuntos
Benzoxazinas/química , Integrina alfaVbeta3/antagonistas & inibidores , Isoquinolinas/química , Quinazolinas/química , Benzoxazinas/síntese química , Benzoxazinas/farmacologia , Desenho de Fármacos , Ensaio de Imunoadsorção Enzimática , Isoquinolinas/síntese química , Isoquinolinas/farmacologia , Quinazolinas/síntese química , Quinazolinas/farmacologia , Relação Estrutura-Atividade
10.
Thromb Haemost ; 98(6): 1309-15, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18064329

RESUMO

Recently, we cloned from platelet mRNA a novel cyclooxygenase (COX)-2 splice variant, designated COX-2a, which is characterized by a partial deletion of exon 5. Preliminary studies of mRNA distribution of COX-2 isoforms in platelets from coronary artery bypass grafting (CABG) patients showed a variable increase in COX-2a mRNA expression after cardiac surgery. Thus, we assessed whether this variant may play a functional role in these patients. We report a marked (about 200-fold) increase in the expression of COX-2a mRNA after CABG. Evidence is presented that ribosomal frame-shifting may correct the coding sequence resulting in the expression of a full-length COX-2a protein. In addition, a reading frame-corrected COX-2a mutant (COX-2a delta G) was generated by site-directed mutagenesis and expressed in COS-7 cells using an adenoviral expression system. However, COX-2a protein was not active in terms of prostaglandin formation. Thus, alternative mRNA splicing might represent an intriguing posttranscriptional mechanism to oppose a transcriptional activation of the COX-2 gene. Evolutionary, this mechanism may prevent COX-2-dependent thromboxane synthesis in the platelet, which would potentiate the likelihood of thrombosis; pharmacologically, this mechanism would prevent an aspirin-insensitive pathway of thromboxane formation.


Assuntos
Processamento Alternativo , Plaquetas/enzimologia , Ponte de Artéria Coronária , Doença da Artéria Coronariana/cirurgia , Ciclo-Oxigenase 2/sangue , RNA Mensageiro/sangue , Administração Oral , Animais , Aspirina/administração & dosagem , Sequência de Bases , Plaquetas/efeitos dos fármacos , Células COS , Chlorocebus aethiops , Doença da Artéria Coronariana/tratamento farmacológico , Doença da Artéria Coronariana/enzimologia , Ciclo-Oxigenase 2/genética , Resistência a Medicamentos , Epoprostenol/metabolismo , Mudança da Fase de Leitura do Gene Ribossômico , Humanos , Isoenzimas/sangue , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Conformação de Ácido Nucleico , Agregação Plaquetária/efeitos dos fármacos , Inibidores da Agregação Plaquetária/administração & dosagem , Tromboxano A2/metabolismo , Transfecção , Resultado do Tratamento , Regulação para Cima
11.
Platelets ; 18(7): 528-34, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17957569

RESUMO

Platelet function and response to pharmacological inhibition are altered by cardiac surgery. For example, aggregation is increased early after aortic valve replacement (AVR) and platelet response to aspirin is often insufficient after coronary artery bypass grafting (CABG). We hypothesized that the effect of aspirin administration after cardiac surgery might be impaired due to platelet activation. Therefore, the antiplatelet effect of aspirin was compared in patients (n = 20 per group) after CABG and AVR surgery (bileaflet prosthesis). Arachidonic acid-induced aggregation (turbidimetry) and thromboxane formation (radioimmunoassay) were determined before and 1, 5, and 10 days after surgery. In CABG-patients, antiplatelet treatment had been discontinued 10 days before surgery. Oral aspirin was started on day 1 after CABG. AVR-patients did not receive oral aspirin. Before surgery, platelet aggregation and thromboxane formation were significantly higher in patients with aortic stenosis. After CABG, thromboxane formation was not significantly changed from control values before surgery (66 +/- 13% on day 10) despite oral aspirin treatment, whereas thromboxane formation in patients undergoing AVR significantly increased compared to values before surgery (216 +/- 29% on day 10). In both groups of patients, 100 micromol/l aspirin in vitro largely inhibited platelet function before surgery, with markedly attenuated effects after surgery. In conclusion, thromboxane formation increased after AVR but not after CABG. The antiplatelet effect of aspirin, therefore, may be impaired after CABG by increased platelet activity. An additional in vitro "resistance" of platelets was seen after both CABG and AVR.


Assuntos
Aspirina/farmacologia , Ponte Cardiopulmonar/efeitos adversos , Ponte de Artéria Coronária/efeitos adversos , Ativação Plaquetária , Inibidores da Agregação Plaquetária/farmacologia , Agregação Plaquetária , Tromboxanos/metabolismo , Valva Aórtica/cirurgia , Humanos , Ativação Plaquetária/efeitos dos fármacos , Ativação Plaquetária/fisiologia , Agregação Plaquetária/efeitos dos fármacos , Agregação Plaquetária/fisiologia , Estudos Prospectivos
13.
Eur J Cardiothorac Surg ; 27(4): 606-10, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15784358

RESUMO

OBJECTIVE: 'Off-pump' coronary artery bypass grafting (OPCAB) is an alternative to conventional coronary artery bypass grafting (CABG) using cardiopulmonary bypass (CPB). While midterm results after OPCAB have become available, systematic studies of changes in platelet function after OPCAB are still missing. Since we have previously shown that oral aspirin treatment (100mg) does not achieve sufficient platelet inhibition in the majority of patients operated on with CPB, we hypothesized that bypass surgery without CPB (off-pump coronary artery bypass, OPCAB) causes less impairment of platelet inhibition by aspirin. The aim of this study was to investigate platelet function and the antiplatelet effect of aspirin after off-pump coronary artery bypass grafting in comparison with conventional on-pump surgery. METHODS: We compared platelet function (in vitro aggregation and thromboxane formation) before and at days 1 and 5 after coronary artery bypass grafting, performed with (n=15) or without (n=14) CPB. Oral aspirin treatment (100mg/d) was started at day 1 after surgery. RESULTS: After a 5 day oral treatment with aspirin, platelet aggregation was inhibited significantly in OPCAB-patients to 55.7+/-16.3% of control before surgery (P<0.05), whereas aggregation remained unchanged after CPB (105.8+/-26.9% of control before surgery; P>0.05). Since aspirin primarily inhibits platelet thromboxane formation, thromoboxane was determined after in vitro aggregation. According to platelet aggregation, thromboxane formation was only inhibited significantly after OPCAB (29.2+/-13.0% of control before surgery, P<0.05), but not after CPB (74.5+/-21.4% of control before surgery, P>0.05). This resistance to aspirin after CPB may be caused by an increased release of new platelets which are competent to form thromboxane, since the number of platelets decreased from 237+/-11x10(3)/microl before CPB to 174+/-13x10(3)/microl at day 1 after surgery and increased significantly the following days reaching 303+/-17x10(3)/microl at day 5. Platelet counts of patients operated on without CPB showed no significant changes (236+/-16x10(3)/microl before OPCAB, 220+/-16x10(3)/microl at day 1 and 266+/-31x10(3)/microl at day 5 after surgery). CONCLUSIONS: The antiplatelet effect of aspirin is largely impaired after CPB, but not after CABG without CPB. Hence, increased platelet turnover after CPB seems to contribute to aspirin resistance, since an increased number of platelets might be competent to form thromboxane within the dosing intervals.


Assuntos
Aspirina/farmacologia , Plaquetas/efeitos dos fármacos , Ponte Cardiopulmonar , Ponte de Artéria Coronária/métodos , Inibidores da Agregação Plaquetária/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Idoso , Plaquetas/metabolismo , Plaquetas/fisiologia , Células Cultivadas , Ponte de Artéria Coronária sem Circulação Extracorpórea , Resistência a Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Agregação Plaquetária/fisiologia , Contagem de Plaquetas , Cuidados Pós-Operatórios , Período Pós-Operatório , Tromboxanos/biossíntese
14.
Phytochemistry ; 64(3): 709-16, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-13679093

RESUMO

Novel flavonoids were formed in young leaves of apple (Malusxdomestica) after treatment with the dioxygenase inhibitor prohexadione-Ca, which is known to reduce the incidence and severity of fire blight caused by Erwinia amylovora and other plant diseases. The compounds were isolated and identified as luteoliflavan, luteoliflavan 5-glucoside, eriodictyol 7-glucoside and 6"-O-trans-p-coumaroyleriodictyol 3'-glucoside. These flavonoids represent a novel biosynthetic pathway in apple leading to the formation of 3-deoxyflavans. Concomitantly, the content of regularly occurring phenylpropanoids is also influenced by prohexadione-Ca with increasing amounts of hydroxycinnamic acids and decreasing flavan-3-ols and flavonols. The altered flavonoid metabolism may be related to the lowered pathogen incidence though the isolated novel flavonoids do not exhibit antibacterial activity.


Assuntos
Inibidores Enzimáticos/farmacologia , Flavonoides/biossíntese , Ácidos Cetoglutáricos/metabolismo , Ácidos Cetoglutáricos/farmacologia , Malus/metabolismo , Oxigenases/antagonistas & inibidores , Ácido Clorogênico/análise , Ácidos Cumáricos/análise , Ácidos Cumáricos/química , Flavanonas/análise , Flavanonas/química , Flavonoides/análise , Flavonoides/química , Flavonoides/metabolismo , Malus/efeitos dos fármacos , Ressonância Magnética Nuclear Biomolecular , Folhas de Planta/efeitos dos fármacos , Folhas de Planta/metabolismo , Espectrofotometria Ultravioleta , Fatores de Tempo
15.
Br J Haematol ; 117(2): 424-6, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-11972528

RESUMO

There are conflicting reports about the expression of cyclooxygenase (COX)-2 in human platelets. The present study describes a flow cytometric method for the measurement of platelet COX. Both COX-1 and COX-2 were shown to be expressed in platelets from patients undergoing a coronary artery bypass graft. There was a significant increase in COX-2 expression at day 5 as compared with pre-surgery values (mean fluorescence 12.31 +/- 0.88 versus 9.15 +/- 0.88; means +/- SEM, n = 7, P < 0.05), whereas COX-1 levels did not change (13.45 +/- 1.11 versus 12.38 +/- 1.41; n = 7, P > 0.05).


Assuntos
Plaquetas/enzimologia , Ponte de Artéria Coronária , Doença das Coronárias/enzimologia , Ativação Enzimática , Isoenzimas/análise , Prostaglandina-Endoperóxido Sintases/análise , Aspirina/metabolismo , Doença das Coronárias/metabolismo , Ciclo-Oxigenase 1 , Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase 2 , Inibidores de Ciclo-Oxigenase/metabolismo , Citometria de Fluxo/métodos , Humanos , Proteínas de Membrana , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA